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ABSTRACT 
Depression is a mood disorder which can affect 1 in every 4 women at some point of life even during pregnancy. Depression is most often not 
properly diagnosed during pregnancy as it is assumed by people to be just another type of imbalance in hormones. But this assumption can be very 
dangerous to the mother and the fetus. The health care professionals are very cautious about the treatment for depression in pregnancy as both 
uses of antidepressant and untreated depression in pregnancy can lead to risks for the unborn baby. This review focuses on the complications 
associated with both treated and untreated depression during pregnancy. In addition, if the treatment is inevitable, then factors such as 
teratogenesis, withdrawal symptoms, neurobehavioral effects, risk of untreated and risk of discontinuing the medication need to be considered 
before selecting the suitable therapy. 
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INTRODUCTION 
Pregnancy is supposed to be one of the happiest moments in a 
women’s life, but many women face confusion, fear, stress and 
even depression during this time. Just like any other clinical 
depression, the depression during pregnancy is also a mood 
disorder. The hormonal changes during pregnancy can affect the 
chemicals in the brain, which is directly linked to depression [1]. 
The diagnosis of depression in pregnancy is most often not 
properly done as it is very difficult to differentiate between 
depression and other hormonal imbalance. Both untreated 
depression and use of antidepressants during pregnancy may have 
ill effects on both the mother and the fetus [2]. The depression 
during pregnancy and the postnatal period carries significant 
adverse effect on the mother as well as the offspring. Studies have 
found out that pregnant women who took antidepressants were 
more likely to have babies with reduced size of the head and had 
twice the chance of having a preterm birth compared to pregnant 
women who were not taking antidepressants. However, in 
contrast, pregnant women with untreated depression were more 
likely to have babies who had both smaller size of body and 
reduced fetal head growth [3]. Hence, this study was designed to 
find the complications associated with both treated and untreated 
depression in pregnant women and the factors that need to be 
considered while deciding the pharmacotherapy for depression. 
Prevalence of depression in pregnancy and possible triggers 
Depression is twice as common in women compared to men, and it 
frequently occurs during the childbearing time. The women with 
pre-existing depression are at a higher risk of getting depression 
during pregnancy and post-partum period. About 14-23% of women 
experience depressive symptoms during pregnancy [4]. 
The possible triggers for depression during pregnancy include [5]: 
• Personal or family history of depression 
• Any relationship problems 
• Treatment for infertility 
• Loss of previous pregnancy 
• Complications in pregnancy 
• Stressful events in life 
• History of abuse or trauma 
Risk of maternal depression on the infant 
The presence of depression and the use of antidepressant 
medication during pregnancy is found to be associated with negative 
effects on the infants [6, 7]. The baby born to a depressed woman is 
found to be more agitated and less active and decreased 
attentiveness compared to the infant born to a woman without 
depression [8-10]. Untreated depression in pregnant women can 
cause premature birth, low birth weight and many other 
developmental problems in the fetus [11]. The postnatal depression 
in women can lead to poor cognitive and language development in 
the infant. They are found to have declined I. Q and insecure 
attachments. Postnatal depression in a mother can lead to negative 
parenting and suicidal behavior. They have a poor parent, child 
interaction [12, 13]. Research has found that the prevention on 
maternal depression can prevent infant problems of maternal 
depression-like behavioral problems, insecure attachments, etc. 
Signs of depression in pregnancy 
The pregnant women with depression may experience some of the 
following signs and symptoms for about two weeks or more [14, 15]: 
• Persistent sadness 
• Either sleeping too little or too much 
• Difficulty in concentrating 
• Loss of interest in activities that was usually enjoyed 
• Feeling of worthlessness or hopelessness 
• Recurring suicidal thoughts and death wishes 
• Guilty feeling 
• Change in the eating habits 
Treatment option for pregnant depressed women 
The various treatment options available for depressed pregnant 
women are [16, 5]; 
• Support groups 
• Psychotherapy 
• Medications 
• Light therapy 
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• Lifestyle modifications 
Due to the less availability of information regarding the safety and 
long-term effects of the use of antidepressant medications in 
pregnant women, many women are interested in other natural ways 
to treat depression.  
A woman having mild to moderate depression can control her 
depressive symptoms with the help of support groups, 
psychotherapy, and light therapy and lifestyle modifications [17, 18]. 
• Exercise- It helps in increasing the serotonin levels naturally 
and decreases the cortisol levels 
• Adequate rest- Establishment of a daily schedule for sleep 
greatly improves the body’s and mind’s ability to handle stress and 
daily challenges 
• Diet and nutrition- Some foods like caffeine, sugar, artificial 
additives, and processed carbohydrates can lead to problems in 
mental and physical health. So a proper and healthy diet helps in 
managing depression. 
• Acupuncture- Studies have found that acupuncture can treat 
depression in pregnant women to some extent. It is a practice in 
which tiny needles are placed into the areas in the body that are 
thought to influence the mood. 
• Light therapy- In this therapy, the pregnant women is exposed 
to artificial lights at specific times of the day to help them relieve the 
depressive symptoms. 
• Omega-3 fatty acids- It has many health benefits and recent 
studies have shown that taking a daily supplement of omega-3 fatty 
acids can decrease the symptoms of depression. 
• Herbal remedies- many herbal supplements and vitamin 
supplements are available which can affect the mood and it can 
change the serotonin levels. 
Choice of antidepressant in pregnancy 
Severe depression in pregnant women needs a combination of 
psychotherapy and medications. While treating major depression, 
the benefits and risk of the medications should be clearly examined 
[19]. The drug, which provides maximum effect and less risk to the 
fetus, should be selected. The other factors that should be 
considered while starting or stopping of antidepressant drugs are:  
• Teratogenicity 
• Toxicity to the neonate or the withdrawal syndrome 
• Neurobehavioral effects 
• The risk of untreated depression in pregnancy 
• The risk of discontinuing the medicine 
Teratogenicity 
The studies have shown that there is no teratogenic effect of 
selective serotonin reuptake inhibitors (SSRIs) and tricyclic 
antidepressants (TCAs). There is no evidence to support that use of 
SSRI and TCA during pregnancy increased the chance of intrauterine 
fetal death or increased risk of major malformations [19, 20]. The 
recent studies have shown that there is a possible risk of birth 
abnormalities with the use of paroxetine, and there are chances of 
development of pulmonary hypertension with fluoxetine. SSRI’s is 
found to be associated with decreased gestational age and low birth 
weight [21, 22]. 
Toxicity to neonate 
There are many reports suggesting that the use of SSRI’s, SNRI’s 
during the late pregnancy is associated with neonatal withdrawal 
syndrome and poor neonatal adoption. The use of TCA during the 
third trimester was found to cause neonatal withdrawal effects like 
agitation, irritability, and seizures. But untreated depression during 
pregnancy can also predispose these problems [23, 24]. 
Neurobehavioral effects 
Studies have shown that the infant born to the mother who was 
under Fluoxetine throughout the pregnancy showed no detectable ill 
effects on cognition, language development or temperament 
whereas the infant born to untreated mother was found to have 
poor cognition and language development [3]. The use of a tricyclic 
antidepressant during pregnancy had no effect on the I. Q, language 
development, cognition of the children, whereas untreated 
depression was found to be associated with poor cognition and 
language development in neonate children [24]. 
The risk of untreated depression during pregnancy 
The studies have found a relationship between untreated depression 
in pregnancy and the adverse effects seen in the mother and the 
fetus. Maternal depression, acting as a stressor can affect the fetal 
development by its action on the hypothalamus, pituitary, adrenal 
and adrenocorticotropic hormones and the beta endorphins [25]. 
Postnatal depression of the mother is associated with problems like 
insecure attachment and declining I. Q in the child. The other 
adverse effect of untreated depression in pregnancy includes 
suicidal thoughts, inadequate self-care, abuse of substance, poor 
adherence to the prenatal care, spontaneous abortion, hypertension, 
pre-eclampsia, intrauterine growth retardation, preterm birth, low 
birth weight of the newborn, depressive behavior in the infant and 
postpartum depression [26]. 
Risk of discontinuing the medication 
The discontinuation of the antidepressant medication can lead to 
increase in the risk of relapse of depression. The women who 
continued the medication throughout the pregnancy showed a lesser 
relapse rate compared to the pregnant women who discontinued the 
medication [27]. 
Antidepressants used  
Depression is one of the most commonly seen mood disorder in 
pregnant women. The pregnant women with severe depression are 
given antidepressant drugs as untreated depression in pregnancy 
may lead to an adverse effect on the mother and the fetus. The 
relapse rate on discontinuing the medications is also high [27]. The 
use of antidepressants during the first trimester of the pregnancy is 
found to be associated with increased chances of miscarriage. The 
commonly used antidepressant drugs during pregnancy are 
selective serotonin reuptake inhibitors, serotonin/norepinephrine 
reuptake inhibitors, and tricyclic antidepressants. 
Antidepressant therapy during lactation may also pose a problem as 
all the psychotropic drugs are found in the breast milk and is 
exposing it to the nursing infant. The commonly used antidepressant 
medications in postnatal women are SSRI’s and SNRI’s. Even though 
all the SSRI are found in breast milk, no serious adverse effect of its 
use has been found in children. The medications like citalopram and 
fluoxetine are found the highest compared to sertraline and 
fluvoxamine in breast milk [28]. There are no evidence suggesting 
the short-term toxic effect of TCA on infant other than doxepin and 
there are no long-term developmental adverse effects also. The 
preferred tricyclic antidepressant during breastfeeding is 
amitriptyline and imipramine. 
Selective serotonin reuptake inhibitors and serotonin/ 
norepinephrine reuptake inhibitors 
This group of antidepressants are the most studied class of 
antidepressant for their use in pregnancy. Until 2005, SSRI was 
thought to be relatively safe for the use in pregnant women as there 
was no congenital anomalies observed compared to those not 
exposed to the antidepressants [28]. But in the recent year, there are 
many concerns regarding the safety of the SSRI as the drug 
paroxetine was suspected to increase the risk of structural 
malformations in fetuses’, especially cardiac anomalies. The recent 
studies have shown that there is a significant relationship between 
the exposure to paroxetine prenatally and the risk of developing 
hypospadias [29]. The other SSRI like fluoxetine, sertraline and 
citalopram have shown to increase the risk of fetal cardiac defects, 
but the data available regarding escitalopram are reassuring. The 
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results of the studies done on the safety of use of venlafaxine during 
pregnancy showed no significant increase in the risk of teratogenic 
effect [30, 31]. 
The use of SSRI and SNRI during the late pregnancy has been 
associated with persistent pulmonary hypertension of the newborn. 
The other complications linked to the use of SSRI and SNRI in the 
late pregnancy are cardiac, respiratory, neurological, gastro-
intestinal and metabolic anomalies either due to toxicity or 
withdrawal phenomena. It is also associated with preterm birth and 
low birth weight. But in general, SSRI are the first-line drugs for the 
treatment of depression in pregnant women as more data are 
available about their safety compared to any other class of 
antidepressant medications [32]. 
Tricyclic antidepressants 
The tricyclic antidepressants act by increasing the availability of 
norepinephrine by blocking the reuptake of serotonin and by 
increasing the sensitivity of the postsynaptic neurons to serotonin. 
There is evidence available for the association of use of 
clomipramine and fetal cardiac defects, but there are no other 
definitive data regarding the safety of other TCA drugs [33]. There is 
an increased risk of developing prenatal antidepressant exposure 
syndrome in neonates exposed to the tricyclic antidepressants 
during the late stage of pregnancy. 
Other antidepressants 
The other antidepressant drugs available are monoamine oxidase 
inhibitors, but they are less commonly used. MAOI’s act by inhibiting 
the degradation of monoamine oxidase. This class of antidepressants 
is used for patients with refractory depression due to their poor 
safety and side effect profile. 
CONCLUSION 
Depression is one of the most common mood disorder seen in 
pregnant women. Both the untreated depression and the use of 
antidepressant drugs may lead to an adverse effect on the mother 
and the fetus. The advantage of antidepressant therapy over the 
effects of untreated depression should be considered while selecting 
the treatment for depression in pregnancy. The treatment of 
depression in pregnant women is a challenge for the physician due 
to the ill effects that can occur to the fetus. While treating the 
depression in pregnant women the physician should consider the 
severity of the illness, the effect of medication on the fetus, the effect 
of withdrawal syndrome, the chances of relapse, etc. The lack of 
proper information regarding the safety of the anti-depressants 
drugs makes the treatment all the more difficult. Untreated 
depression can lead to developmental defects like poor cognition, 
poor language development and a sense of insecurity in the infant. 
The use of antidepressant drugs may cause some of the problems 
like pulmonary hypertension of the newborn, cardiac anomalies, low 
birth weight, etc. The infant whose mother was under 
antidepressant drugs showed better cognition, language 
development, I. Q, lesser agitation, lesser irritability compared to the 
infant of an untreated depressive mother. The SSRI and TCA drugs 
are relatively safe to be used during pregnancy, although it is 
recommended to reduce their dose the last trimester due to the risk 
of premature birth and low birth weight. With effective surveillance 
and management, the ill effects to the fetus due to the 
antidepressant use in pregnancy can be controlled. The toxic effects 
and withdrawal syndrome in the infants can be managed with 
proper follow-up and surveillance. The health care professional 
should be careful while treating the depression during pregnancy 
and lactation. 
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